Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
Saved in:
| Title: | Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). |
|---|---|
| Authors: | Strober, Bruce1,2 (AUTHOR) brucestrober30@me.com, Bachelez, Hervé3,4 (AUTHOR), Crowley, Jeffrey5 (AUTHOR), Elewski, Boni E.6 (AUTHOR), Gooderham, Melinda7 (AUTHOR), Menter, Alan8 (AUTHOR), Strohal, Robert9 (AUTHOR), Chen, Michael M.10 (AUTHOR), Wu, Tianshuang10 (AUTHOR), Zhan, Tianyu10 (AUTHOR), Photowala, Huzefa10 (AUTHOR), Armstrong, April11 (AUTHOR) |
| Source: | Journal of the European Academy of Dermatology & Venereology. May2024, Vol. 38 Issue 5, p864-872. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
